340 related articles for article (PubMed ID: 21591319)
1. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
Kleber ME; Grammer TB; März W
MMW Fortschr Med; 2010 Jul; 152 Suppl 2():47-55. PubMed ID: 21591319
[TBL] [Abstract][Full Text] [Related]
2. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
3. Refocusing on use of cholesteryl ester transfer protein inhibitors.
Kastelein JJ
Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
[TBL] [Abstract][Full Text] [Related]
4. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
5. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
6. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein (CETP) inhibitors.
Hunt JA; Lu Z
Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458
[TBL] [Abstract][Full Text] [Related]
9. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
11. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Schaefer EJ
Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
[TBL] [Abstract][Full Text] [Related]
12. Controversy on high density lipoprotein raising therapy.
Cucuianu M; Brudaşcă I
Rom J Intern Med; 2010; 48(2):111-6. PubMed ID: 21428174
[TBL] [Abstract][Full Text] [Related]
13. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
14. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
15. [HDL and CETP in atherogenesis].
Pöss J; Böhm M; Laufs U
Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
[TBL] [Abstract][Full Text] [Related]
16. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
[TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Chapman MJ; Le Goff W; Guerin M; Kontush A
Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
[TBL] [Abstract][Full Text] [Related]
18. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Brousseau ME; Diffenderfer MR; Millar JS; Nartsupha C; Asztalos BF; Welty FK; Wolfe ML; Rudling M; Björkhem I; Angelin B; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1057-64. PubMed ID: 15761191
[TBL] [Abstract][Full Text] [Related]
19. The potential for CETP inhibition to reduce cardiovascular disease risk.
Ansell B; Hobbs FD
Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase.
Nakamura Y; Kotite L; Gan Y; Spencer TA; Fielding CJ; Fielding PE
Biochemistry; 2004 Nov; 43(46):14811-20. PubMed ID: 15544352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]